{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:09:51Z","timestamp":1791846591303,"version":"4.3.4"},"reference-count":73,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID), is widely prescribed for pain management due to its efficacy and improved gastrointestinal safety profile compared to traditional NSAIDs. Understanding prescription trends and their comparison to other NSAIDs provides valuable insight into prescribing behaviors in clinical settings. Methods: This retrospective study analyzed celecoxib prescriptions written by three pain management physicians in a single institution over a 16-month period from 1 January 2023 to 30 April 2024. Prescription data were collected and grouped into four 4-month intervals to assess temporal trends. Additionally, we compared celecoxib prescriptions to other commonly prescribed NSAIDs, including ibuprofen, meloxicam, naproxen, and diclofenac. Results: A total of 143 celecoxib prescriptions were identified during the study period, with a steady increase observed across consecutive intervals: 8 prescriptions from January\u2013April 2023, 22 from May\u2013August 2023, 46 from September\u2013December 2023, and 67 from January\u2013April 2024. In comparison, a total of 165 prescriptions were written for other NSAIDs over the same period, with 26 prescriptions from January\u2013April 2023, 41 from May\u2013August 2023, 45 from September\u2013December 2023, and 53 from January\u2013April 2024. While prescriptions for both celecoxib and other NSAIDs increased over time, the rate of celecoxib prescriptions showed a steeper rise. Conclusions: The findings demonstrate a notable increase in celecoxib prescriptions in this pain management clinic, outpacing the growth of other NSAIDs. This trend may reflect increasing provider preference for COX-2 selective inhibitors due to their favorable safety profile and efficacy. Further research is warranted to explore the underlying factors driving these prescribing patterns.<\/jats:p>","DOI":"10.3390\/jcm14082823","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:24:16Z","timestamp":1745180656000},"page":"2823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Trends in Celecoxib Prescribing: A Single Institution 16-Month Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Ivo H.","family":"Cerda","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-6460","authenticated-orcid":false,"given":"Helen","family":"Jung","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine & Rehabilitation, Larking Community Hospital, South Miami, FL 33143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0681-8941","authenticated-orcid":false,"given":"Rodrigo","family":"Diez Tafur","sequence":"additional","affiliation":[{"name":"Pain Management Unit, Cl\u00ednica Angloamericana, San Isidro 15073, Peru"},{"name":"Centro MDRS: Sports, Spine & Pain Centers, Miraflores 15073, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-9621","authenticated-orcid":false,"given":"Robert Jason","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-9056","authenticated-orcid":false,"given":"Christopher L.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal J.","family":"Hasoon","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care, and Pain Medicine, UTHealth, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E328","DOI":"10.1097\/j.pain.0000000000002291","article-title":"Prevalence of chronic pain among adults in the United States","volume":"163","author":"Yong","year":"2022","journal-title":"Pain"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ejp.2234","article-title":"The costs of chronic pain-Long-term estimates","volume":"28","author":"Stubhaug","year":"2024","journal-title":"Eur. J. Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.pain.2012.05.009","article-title":"Self-perceived burden in chronic pain: Relevance, prevalence, and predictors","volume":"153","author":"Kowal","year":"2012","journal-title":"Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: An update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2374373518786013","article-title":"Impact of Chronic Pain on Patients\u2019 Quality of Life: A Comparative Mixed-Methods Study","volume":"6","author":"Hadi","year":"2019","journal-title":"J. Patient Exp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","article-title":"Prevalence and Profile of High-Impact Chronic Pain in the United States","volume":"20","author":"Pitcher","year":"2019","journal-title":"J. Pain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/papr.13220","article-title":"Associations between chronic pain, anxiety, and depression among adults in the United States","volume":"23","author":"Mullins","year":"2023","journal-title":"Pain Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jpain.2012.03.009","article-title":"The economic costs of pain in the United States","volume":"13","author":"Gaskin","year":"2012","journal-title":"J. Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jama.2020.0734","article-title":"US Health Care Spending by Payer and Health Condition, 1996\u20132016","volume":"323","author":"Dieleman","year":"2020","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shi, Y., and Wu, W. (2023). Multimodal non-invasive non-pharmacological therapies for chronic pain: Mechanisms and progress. BMC Med., 21.","DOI":"10.1186\/s12916-023-03076-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/j.pain.0000000000001737","article-title":"Alterations in pronociceptive and antinociceptive mechanisms in patients with low back pain: A systematic review with meta-analysis","volume":"161","author":"McPhee","year":"2020","journal-title":"Pain"},{"key":"ref_13","first-page":"3","article-title":"Mechanism of action of antiinflammatory drugs","volume":"20","author":"Vane","year":"1998","journal-title":"Int. J. Tissue React."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.18773\/austprescr.2017.037","article-title":"Peptic ulcer disease and non-steroidal anti-inflammatory drugs","volume":"40","author":"Drini","year":"2017","journal-title":"Aust. Prescr."},{"key":"ref_15","first-page":"CD009865","article-title":"Celecoxib for osteoarthritis","volume":"5","author":"Puljak","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/acr.22753","article-title":"Clinical Efficacy of Celecoxib Compared to Acetaminophen in Chronic Nonspecific Low Back Pain: Results of a Randomized Controlled Trial","volume":"68","author":"Bedaiwi","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.joca.2008.04.009","article-title":"Responder analysis and correlation of outcome measures: Pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis","volume":"16","author":"Bingham","year":"2008","journal-title":"Osteoarthr. Cartil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2006.065128","article-title":"Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: Multicentre randomised controlled trial","volume":"66","author":"Rother","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"Bingham","year":"2007","journal-title":"Rheumatology"},{"key":"ref_21","first-page":"352","article-title":"Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis","volume":"22","author":"Huang","year":"2020","journal-title":"Pain Med. Off. J. Am. Acad. Pain Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3899\/jrheum.080073","article-title":"A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis","volume":"36","author":"Foeldvari","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_23","unstructured":"(2025, February 24). Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations, Available online: https:\/\/www.hhs.gov\/sites\/default\/files\/pain-mgmt-best-practices-draft-final-report-05062019.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2023","journal-title":"MMWR Recomm. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","article-title":"Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee","volume":"98","author":"Price","year":"2022","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr.24131","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee","volume":"72","author":"Kolasinski","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_27","first-page":"284","article-title":"WHO Analgesic Ladder","volume":"38","author":"Anekar","year":"2023","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study","volume":"119","author":"Singh","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1177\/147323000903700615","article-title":"The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: Results from two randomized, double-blind, 6-week studies","volume":"37","author":"Ekman","year":"2009","journal-title":"J. Int. Med. Res."},{"key":"ref_30","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","article-title":"Celecoxib: A review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: Results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semarthrit.2007.03.004","article-title":"A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis","volume":"37","author":"Kivitz","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib Pathways: Pharmacokinetics and Pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenetics Genom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib. A selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm960803q","article-title":"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-trifluoromethyl- 1H-pyrazol- l-yl]benzene sulfonamide (SC-58635, celecoxib)","volume":"40","author":"Penning","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0149-2918(00)80005-3","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/gut.47.6.762","article-title":"Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa","volume":"47","author":"Jackson","year":"2000","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac","volume":"89","author":"White","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cheng, B.-R., Chen, J.-Q., Zhang, X.-W., Gao, Q.-Y., Li, W.-H., Yan, L.-J., Zhang, Y.-Q., Wu, C.-J., Xing, J.-L., and Liu, J.-P. (2021). Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0261239"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/apt.14610","article-title":"Randomised clinical trial: Gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial","volume":"47","author":"Yeomans","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ehjcvp\/pvac015","article-title":"Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: Insights from the PRECISION trial","volume":"8","author":"Obeid","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Choi, I.A., Baek, H.-J., Cho, C.-S., Lee, Y.-A., Chung, W.T., Park, Y.E., Lee, Y.J., Park, Y.-B., Lee, J., and Lee, S.-S. (2014). Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: A 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-375"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","article-title":"Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial","volume":"376","author":"Chan","year":"2010","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J.A., Bombardier, C., Cannon, C., and Farkouh, M.E. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet, 382, 769\u2013779.","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jpain.2021.07.012","article-title":"Prevalence, Incidence, and Factors Associated With Non-Specific Chronic Low Back Pain in Community-Dwelling Older Adults Aged 60 Years and Older: A Systematic Review and Meta-Analysis","volume":"23","author":"Wong","year":"2022","journal-title":"J. Pain"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Xu, Y., and Wu, Q. (2021). Prevalence trend and disparities in rheumatoid arthritis among us adults, 2005\u20132018. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153289"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021","volume":"5","author":"Steinmetz","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.2337\/db14-0020","article-title":"Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions","volume":"63","author":"Halter","year":"2014","journal-title":"Diabetes"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Russo, G.T., De Cosmo, S., Viazzi, F., Mirijello, A., Ceriello, A., Guida, P., Giorda, C., Cucinotta, D., Pontremoli, R., and Fioretto, P. (2018). Diabetic kidney disease in the elderly: Prevalence and clinical correlates. BMC Geriatr., 18.","DOI":"10.1186\/s12877-018-0732-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MCO.0000000000000238","article-title":"The Aging Gastrointestinal Tract","volume":"19","author":"Soenen","year":"2016","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","article-title":"Accounting for Age in the Definition of Chronic Kidney Disease","volume":"181","author":"Liu","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-021-01069-z","article-title":"Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood Flow","volume":"61","author":"Soejima","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jpain.2022.01.006","article-title":"Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014\u20132018","volume":"23","author":"Gorfinkel","year":"2022","journal-title":"J. Pain"},{"key":"ref_59","first-page":"1","article-title":"Prescription Opioid Use Among Adults With Chronic Pain: United States, 2019","volume":"162","author":"Dahlhamer","year":"2019","journal-title":"Natl. Health Stat. Rep. Number"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11481-021-10046-z","article-title":"Opioid Use, Gut Dysbiosis, Inflammation, and the Nervous System","volume":"17","author":"Jalodia","year":"2022","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1001\/archinte.166.19.2087","article-title":"Association Between Mental Health Disorders, Problem Drug Use, and Regular Prescription Opioid Use","volume":"166","author":"Sullivan","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/AJP.0000000000000603","article-title":"Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction","volume":"34","author":"Sullivan","year":"2018","journal-title":"Clin. J. Pain"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jpain.2011.02.357","article-title":"Elevated pain sensitivity in chronic pain patients at risk for opioid misuse","volume":"12","author":"Edwards","year":"2011","journal-title":"J. Pain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104694","DOI":"10.1016\/j.jpain.2024.104694","article-title":"Persistent pain, long-term opioids, and restoring trust in the patient-clinician relationship","volume":"27","author":"Lozano","year":"2025","journal-title":"J. Pain"},{"key":"ref_65","first-page":"150","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States, 2016","volume":"65","author":"Lappin","year":"2023","journal-title":"MMWR Recomm. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10754-021-09307-4","article-title":"Opioid and non-opioid analgesic prescribing before and after the CDC\u2019s 2016 opioid guideline","volume":"22","author":"Encinosa","year":"2022","journal-title":"Int. J. Health Econ. Manag."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40265-020-01369-x","article-title":"The Expanding Role of the COX Inhibitor\/Opioid Receptor Agonist Combination in the Management of Pain","volume":"80","author":"Varrassi","year":"2020","journal-title":"Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bindu, S., Mazumder, S., and Bandyopadhyay, U. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol., 180.","DOI":"10.1016\/j.bcp.2020.114147"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"196159","DOI":"10.1155\/2012\/196159","article-title":"Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel\u2019s View on Preventable Harm Associated with NSAID Therapy","volume":"2012","author":"Taylor","year":"2012","journal-title":"Curr. Gerontol. Geriatr. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.4103\/jfmpc.jfmpc_201_20","article-title":"NSAIDs and self-medication: A serious concern","volume":"9","author":"Doomra","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2146\/ajhp050409","article-title":"Agreement between medical record documentation and patient-reported use of nonsteroidal antiinflammatory drugs","volume":"63","author":"Abdolrasulnia","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/2175-8239-jbn-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"Lucas","year":"2018","journal-title":"Braz. J. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5253623","DOI":"10.1155\/2018\/5253623","article-title":"Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials","volume":"2018","author":"Sriuttha","year":"2018","journal-title":"Int. J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:51Z","timestamp":1760030271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082823"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082823","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}